Dulaglutide
As of the edition of 20 October 2026, Dulaglutide is a protein: marketed, first approved in 2014 (US); acts on GLP1R; US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Protein
- Brand name
- Trulicity
- First approved
- 18 September 2014 (US)
- Approvals on record
- 14 in 5 regions
- Holder of the most recent approval
- Eli Lilly; 3 holders in all
- Registered trials
- 82, 2 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Pregnancy and women's health; Urinary and reproductive; Digestive system; Heart and blood vessels
US protection
US protection ended in 2026.
US protection ended in 2026, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Eli Lilly. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 10 | 1 | 0 |
| Phase 1 | 17 | 17 | 0 | 0 |
| Phase 2 | 12 | 11 | 1 | 0 |
| Phase 3 | 25 | 23 | 2 | 0 |
| Phase 4 | 16 | 10 | 2 | 2 |
| All trials | 82 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Applicant and Lead sponsor of trials | 2008 to now |